New technologies in preclinical trials: accelerating the path to innovative therapies
DOI:
https://doi.org/10.62035/rca.6.81References
Salinas F, Marelli BE, Sanguineti S, Goldbaum F, Muñoz L, Etchevers L, Silvestrini P, Notaro US, Salvetti NR, Zylberman V, Ortega HH. (2022). Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab’)2 fragment derived from equine polyclonal antibodies. Toxicol Appl Pharmacol. 1;434:115796. DOI: https://doi.org/10.1016/j.taap.2021.115796
Soriano Pérez ML, Funes JA, Flores Bracamonte C, Ibarra LE, Forrellad MA, Taboga O, Cariddi LN, Salinas FJ, Ortega HH, Alustiza F, Molina M. (2023) Development and biological evaluation of pNIPAM-based nanogels as vaccine carriers. Int J Pharm. 630:122435. DOI: https://doi.org/10.1016/j.ijpharm.2022.122435
Loos JA, Negro PS, Ortega HH, Salinas FJ, Arán M, Pellizza L, Salerno GL, Cumino AC. Anti-echinococcal effect of metformin in advanced experimental cystic echinococcosis: reprogrammed intermediary carbon metabolism in the parasite. Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0094124. Epub 2024 Sep 12. PMID: 39264188; PMCID: PMC11459915. DOI: https://doi.org/10.1128/aac.00941-24
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Hugo Ortega, Natalia Salvetti

This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
This permits anyone to copy, redistribute, remix, transmit, and adapt the work provided the original work and source are appropriately cited.